Zobrazeno 1 - 10
of 64
pro vyhledávání: '"Toru Ishibashi"'
Autor:
Toru Ishibashi, Kosuke Kawamoto, Kasumi Matsuno, Genki Ishihara, Takamichi Baba, Nobuaki Komori
Publikováno v:
PLoS ONE, Vol 15, Iss 5, p e0233484 (2020)
BACKGROUND:Measurement of the reactive hyperemia index (RHI) using peripheral arterial tonometry (PAT) has shown benefits in the evaluation of vascular endothelial function and prediction of cardiovascular disease prognosis. Thus, it is important to
Externí odkaz:
https://doaj.org/article/1186cf057dbd4c5b872198cc2f7cb59e
Autor:
Toru Ishibashi, Yasutaka Takei, Mamoru Kato, Yukari Yamashita, Atsuko Tsukamoto, Kazuma Matsumoto, Hajime Sakamoto, Takanori Masuda, Osamu Miyazaki
Publikováno v:
Radiation Protection Dosimetry.
To propose reference values for air-kerma at the reference point (Ka,r), air-kerma area product (PKA), fluoroscopy time (FT) and number of cine images (CI) for four age groups in Japan, a nationwide questionnaire was posted to 132 pediatric catheteri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::47c82b785d3b24a48f094608bbb28217
https://doi.org/10.1093/rpd/ncad139
https://doi.org/10.1093/rpd/ncad139
Autor:
Toru Ishibashi, Takanori Masuda, Mamoru Kato, Yukari Yamashita, Yasutaka Takei, Atsuko Tsukamoto, Kazuma Matsumoto, Hajime Sakamoto
Publikováno v:
Radiation Protection Dosimetry. 198:16-22
To propose typical values for the arrhythmia region between pulmonary vein isolation (PVI) and nonpulmonary vein isolation (non-PVI) in Japan. A nationwide questionnaire was posted to 343 facilities, to which 125 facilities (36.4%) responded. Results
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5acb437241bb5b161d9671594df66a3
https://doi.org/10.1093/rpd/ncab185
https://doi.org/10.1093/rpd/ncab185
Baloxavir Treatment in Adolescents With Acute Influenza: Subgroup Analysis From the CAPSTONE-1 Trial
Autor:
Frederick G. Hayden, Takeki Uehara, Simon Portsmouth, Takao Shishido, Kenji Tsuchiya, Masahiro Kinoshita, Toru Ishibashi, Keiko Kawaguchi
Publikováno v:
Journal of the Pediatric Infectious Diseases Society
Background Baloxavir marboxil has demonstrated safety and efficacy in treating adult and adolescent outpatients with acute influenza (CAPSTONE-1 trial). Here, we report a subgroup analysis of outcomes in adolescents from the trial. Methods CAPSTONE-1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35a7667cd8940d8411af722595019a6a
https://doi.org/10.1093/jpids/piaa145
https://doi.org/10.1093/jpids/piaa145
Autor:
Takeshi Noshi, Akira Naito, Makoto Kawai, Ryu Yoshida, Kenji Sato, Yoshinori Ando, Ryoko Oka, Takahiro Hasegawa, Toru Ishibashi, Motoyasu Onishi, Yuki Yoshida, Takao Shishido, Mitsutaka Kitano, Akihiko Sato
Publikováno v:
Journal of Antimicrobial Chemotherapy
Background Baloxavir acid, the active form of the orally available prodrug baloxavir marboxil, is a novel cap-dependent endonuclease inhibitor of influenza virus. Baloxavir marboxil has been shown to rapidly reduce virus titres compared with oseltami
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1144345c997c6f9cee4e0e1f47813139
https://doi.org/10.1093/jac/dkaa393
https://doi.org/10.1093/jac/dkaa393
Autor:
Shun Abe, Kazuaki Osawa, Kaoru Katori, Yohei Sugita, Toru Ishibashi, Takuya Taniguchi, Fuyuki Washizuka
Publikováno v:
Japanese Journal of Radiological Technology. 76:297-303
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77db9ccfc4685e83d34c9807538cbf28
https://doi.org/10.6009/jjrt.2020_jsrt_76.3.297
https://doi.org/10.6009/jjrt.2020_jsrt_76.3.297
Autor:
Nobuo Hirotsu, Kenji Tsuchiya, Takeki Uehara, Takao Shishido, Toru Ishibashi, Akira Watanabe, Hiroki Sakaguchi, Chisako Sato, Keiko Baba, Shinya Omoto, Frederick G. Hayden
Publikováno v:
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Background We assessed the safety and effectiveness of baloxavir marboxil administration in Japanese children with influenza. Methods This open-label study administered 1 weight-adjusted dose of baloxavir to 107 children aged 1–11 years with labora
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0aa1ecfc08e8348644bc7aa4b50f9d3
https://doi.org/10.1093/cid/ciz908
https://doi.org/10.1093/cid/ciz908
Publikováno v:
Journal of Pharmaceutical Sciences. 108:3112-3117
Baloxavir marboxil is a prodrug of baloxavir acid, an inhibitor of cap-dependent endonuclease, and suppresses the replication of influenza virus. The aim of this study was to investigate its pharmacokinetic characteristics in Japanese pediatrics. Pop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::feb88ea73e2998bb0bea2c1021b3caee
https://doi.org/10.1016/j.xphs.2019.04.010
https://doi.org/10.1016/j.xphs.2019.04.010
Autor:
Toru Ishibashi
Publikováno v:
Current Pharmaceutical Design
Background:Molecular hydrogen (H2) is now recognized as a therapeutic gas for the treatment of numerous diseases including neurodegenerative diseases, metabolic disorders, and inflammatory diseases. Nonpolar, neutral H2 is assumed to have health bene
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93cd0048a4fd037ae47be6d53f5de46d
https://doi.org/10.2174/1381612825666190506123038
https://doi.org/10.2174/1381612825666190506123038
Publikováno v:
Journal of Pharmaceutical Sciences. 108:1896-1904
Baloxavir marboxil, a prodrug that is metabolized to baloxavir acid, suppresses viral replication by inhibiting cap-dependent endonuclease. Our aim is to characterize its pharmacokinetics and exposure-response relationships. Population pharmacokineti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ba3b942154165bd27bb2478e7300257
https://doi.org/10.1016/j.xphs.2018.12.005
https://doi.org/10.1016/j.xphs.2018.12.005